TerminatedNCT05839509
Phase 2 Clinical Trial of GH001 in Bipolarity type II
Researchers are studying GH001 to find out how it affects depression symptoms in people with bipolarity type II during a depressive episode.
Medication studyAges 18–64Multiple countries
Understand this study
What is this study about?
Researchers are studying GH001 to find out how it affects depression symptoms in people with bipolarity type II during a depressive episode.
Who could participate?
This study is for people with type II bipolarity. Listed age limits: 18 years to 64 years. Other eligibility criteria apply.
- Listed locations
- Dresden and 6 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 6, 2023
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 6
- Sponsor
- GH Research Ireland Limited
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom, Germany, Netherlands
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT05839509
- Official title
Show the full official title
A Phase 2 Clinical Trial of GH001 in Patients with Bipolar II Disorder and a Current Major Depressive Episode
Recruitment & locations
TerminatedDresden, Germany · Frankfurt, Germany · Münster, Germany
4 more locations
- Leiden, Netherlands
- Maastricht, Netherlands
- London, United Kingdom
- Oxford, United Kingdom
A listed location does not confirm current availability.
Questions about this study
What is this study about?
Researchers are studying GH001 to find out how it affects depression symptoms in people with bipolarity type II during a depressive episode.
Who is behind this study?
The study sponsor is GH Research Ireland Limited.
Does this study involve medication?
Yes. The study involves medication, including GH001.
Who can participate?
This study is for people with type II bipolarity. Listed age limits: 18 years to 64 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
A Phase 2 Clinical Trial of GH001 in Patients with Bipolarity type II and a Current Major Depressive Episode (GH001-BD-202)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder with Mixed Features (Protocol No D1050304)